Latest news with #drugtesting
Health Line
11-07-2025
- Health
- Health Line
How Long Does Molly (MDMA) Stay in Your System?
Molly can be detected in some bodily fluids for up to three days. It may stay in your system longer depending on the dose. The drug may still be found in scalp hair after three months. MDMA, also known as 'molly' or 'ecstasy,' is an illegal, synthetic drug that has similar effects to stimulants like methamphetamine. When molly is ingested, it's quickly absorbed into the bloodstream and can take effect in as little as 15 minutes. The drug is usually detectable in bodily fluids for one to three days after ingestion. However, it may be detected for up to five days or more in some circumstances. Like other drugs, it's detectable in hair for several months. Detection times are based on the time you last took the drug. Taking multiple doses over a period of several hours can lengthen the detection window. Seeking help for addiction may seem daunting or even scary, but several organizations can provide support. If you believe that you or someone close to you is showing signs of addiction, you can contact the following organizations for immediate help and advice: Substance Abuse and Mental Health Services Administration (SAMHSA): 800-662-4357 (TTY: 800-487-4889) 988 Suicide & Crisis Lifeline: 988 How long is molly detectable via drug testing? Molly is detectable in your body for anywhere from around two days to several months after ingestion, depending on the type of drug test used. This is because different drug testing methods have different detection windows. These are based on how the drug is absorbed and broken down in the body. Urine testing Molly is detectable in urine up to three days after ingestion. MDMA that enters the bloodstream is carried to the liver, where it's broken down and excreted. Note that most typical urine tests won't detect MDMA. On the other hand, some medications can cause false positives for MDMA in urine tests. Blood testing Molly can typically be detected in blood for around one to two days after ingestion, though in rare cases it may be detected for slightly longer. It's absorbed quickly into the bloodstream and reaches peak levels two hours after it's taken. Over time, the drug is transported to the liver, where it's broken down. Saliva testing Molly is detectable in saliva for one to two days after ingestion. Since it's typically taken by mouth, it appears quickly in the saliva. Its concentration peaks after two hours before beginning to decrease at four hours. Hair testing Molly is detectable in scalp hair for several months after ingestion. Once in the bloodstream, small amounts of the drug reach the network of tiny blood vessels that feed the hair follicles. Hair grows at a rate of around 1 centimeter (cm) per month, and the segment of hair that tests positive usually corresponds to the time of ingestion. What factors affect how long molly stays in your system? Molly is absorbed, broken down, and eliminated faster or slower depending on several factors. These include the overall amount ingested and whether it's taken in single or multiple doses. Other factors relate to the drug's chemical composition. Molly, also called ecstasy or MDMA, is frequently laced with other illegal drugs or chemical compounds even when it's sold as 'pure.' When ecstasy pills or capsules are combined with other substances, it can affect how long it stays in your system and how long an illegal drug may be detected on a drug screening test. Finally, a variety of individual factors can affect drug metabolism. These include: age metabolism kidney function liver function genes Is there anything you can do to metabolize it faster? There's nothing you can do to metabolize molly faster. Once it enters your system, your liver needs time to break it down. Drinking water doesn't flush molly from your system or neutralize its effects. Exercising after taking molly can lead to dehydration, which can increase liquid consumption. Molly also affects your heart's ability to pump blood, which poses risks during exercise. How long does it take to feel the effects? People may start to feel the effects of molly around 15 minutes after taking it. It takes about three hours to feel the drug's peak effects. Sought-after short-term effects Some of molly's sought-after short-term (acute) effects include: euphoria openness to others extraversion and sociability increased sensory perception increased energy sexual arousal wakefulness Negative short-term effects Other short-term effects are negative. Some of these may appear alongside the drug high, including: muscle cramps increased heart rate increased blood pressure jaw clenching and teeth grinding nausea blurry vision sweating chills Taking a high dose of molly can cause an increase in body temperature. This can sometimes lead to kidney failure, heart failure, or death. Other negative effects can appear during the week after ingesting molly. They may include: loss of appetite blurry vision insomnia anxiety agitation depression lack of focus recklessness How long does it take for the effects of molly to wear off? It takes about three to six hours for a molly high to wear off. Some people take another dose as the effects of the initial dose fade, prolonging the drug high. Molly's negative effects tend to appear later and last longer. Mood disruptions such as irritability, anxiety, and depression can last for up to a week after your last dose. Using molly on a regular basis may lead to effects including depression, heart disease, and reduced cognitive function. However, we still don't know much about the long-term impact. The bottom line Molly usually stays in your system for up to three days, but it can last for months in some cases.
RNZ News
06-07-2025
- RNZ News
Patient not drug tested hours before second killing, father alleges
The man's father alleged that on the day he killed for a second time, he was supposed to be drug tested. Photo: RNZ A mental health patient was not drug tested on the day he committed his second killing because the staffer believed he was "acting cagey", his father alleges. The man was subject to a compulsory treatment order at the time, which meant that drug screening occurred on a voluntary basis. But if he failed the test, the clinician would then need to assess whether the patient should be re-called to hospital. RNZ earlier revealed the man - who was made a special patient under the Mental Health Act after his first killing - was recently found not guilty of murder by reason of insanity for a second time after killing someone he believed was possessed. RNZ is unable to publish details regarding either killings due to an appeal against name suppression that is due to be heard by the Court of Appeal. RNZ has obtained a copy of a letter from the man's father to the presiding judge. Do you know more? Email The man's father alleged that on the day he killed for a second time, he was supposed to be drug tested. "He turned up for the appointment but was not tested because the staff member said that he was acting cagey and she didn't want to make him feel like he was being picked on. "This is a so-called health professional who observed unusual behaviour from a person with severe mental health issues and they didn't do anything about it. She didn't test him and basically allowed him to leave. A few hours later [he killed again]." The man said his son told him he had to go have a drug test "so he was expecting it, but nothing came of it". The man's second killing "could and should have been prevented," the father says. "How can someone who has previously killed another person be able to remain free when the warning signs are right there for all to see?" In the weeks leading up to the second killing, the man's mental health was "rapidly declining", a judge earlier said. He was admitted to a mental health facility following an altercation with a relative. About a week later he was released. He was having relationship problems and was using cannabis. Five days after he was released from the mental health facility, he stabbed someone to death. In his letter, he said his son had mental health issues "for most of his life". "I have attended countless appointments and meetings relating to [him] and his treatment, and I have full knowledge of the process, his medication and it's effectiveness, the downsides and how he has responded over the years. "I have met his doctors and psychiatrists and have a good understanding of the mental health system, what services are provided and some of it's failings." He discussed his son's admission to a mental health facility before the second killing when his mental health "deteriorated". He said the staff should not have released his son. The second killing was "predictable if anyone bothered to look at the warning signs and do something about it," he said. "Predictable in the sense that [he] was on a downward spiral. Maybe not predictable with the exact date and time, but the warning signs were there for the health professionals to see. To use their judgement and training and to actually do something about what they saw instead of just letting it go because it gets too hard for them." He said the health system was "not aggressive enough to make decisions". "For more than 5 years I visited [him] every night in one of their institutions, so I know full well what goes on inside the walls. There are more questions than answers. The health system had [him] in their custody and released him. A health professional saw [him] on the day he killed [again], described him as being cagey, did not do the blood test and let him go without doing anything. How? Who is accountable? How can someone who has previously killed another person be able to remain free when the warning signs are right there for all to see?" RNZ put the allegations regarding the drug test to both Health New Zealand and the Ministry of Health. Health New Zealand (HNZ) said an external review of the care the patient received leading up to their alleged offending is in progress. They did not comment on the allegations. In most situations screening for substance use occurred on a voluntary basis and could include individuals subject to detention under the Mental Health Act on Compulsory Treatment Orders, an HNZ spokesperson said. "However, screening is very much part of an individual treatment/care plan where interventions may be put in place in the event of a positive result or refusal to be tested." Director of Mental Health Dr John Crawshaw said in a statement that in circumstances like these an independent review is triggered to investigate the incident and make recommendations for changes to services and for those recommendations to be acted on. A review was still underway. "The claim of reported drug use and delays in drug testing would be most appropriately investigated by the independent review commissioned by Health New Zealand." In relation to drug testing, a Ministry of Health spokesperson said screening for substance use occurred on a voluntary basis and can include individuals subject to detention under the Mental Health Act on Compulsory Treatment Orders. "Screening is very much part of an individual treatment/care plan where interventions may be put in place in the event of a positive result or refusal to be tested. "For further background, it also depends on whether the person is on an inpatient order or a community treatment order. If the testing is part of a condition of leave on an inpatient order it can result in the leave being cancelled. If the person is on a community treatment order, the responsible clinician would then need to assess whether there is enough concern to direct the patient to be treated as an inpatient. It's important to note that this applies to people under ordinary Mental Health Act orders and there is a separate process for special patients." Mental Health Minister Matt Doocey said any serious incident, particularly one where someone was killed was a "cause of very serious concern". "That is why it is important that reviews are triggered and recommendations for changes to services are acted on. My focus is on ensuring agencies involved are putting in place the necessary changes to help prevent these incidents occurring again. "There is an external review underway, and it would be my expectation that this review will cover the care this person received leading up to the incident." Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
RNZ News
06-07-2025
- RNZ News
Man who killed for second time not drug tested on day of attack
The man's father alleged that on the day he killed for a second time, he was supposed to be drug tested. Photo: RNZ A mental health patient was not drug tested on the day he committed his second killing because the staffer believed he was "acting cagey", his father alleges. The man was subject to a compulsory treatment order at the time, which meant that drug screening occurred on a voluntary basis. But if he failed the test, the clinician would then need to assess whether the patient should be re-called to hospital. RNZ earlier revealed the man - who was made a special patient under the Mental Health Act after his first killing - was recently found not guilty of murder by reason of insanity for a second time after killing someone he believed was possessed. RNZ is unable to publish details regarding either killings due to an appeal against name suppression that is due to be heard by the Court of Appeal. RNZ has obtained a copy of a letter from the man's father to the presiding judge. Do you know more? Email The man's father alleged that on the day he killed for a second time, he was supposed to be drug tested. "He turned up for the appointment but was not tested because the staff member said that he was acting cagey and she didn't want to make him feel like he was being picked on. "This is a so-called health professional who observed unusual behaviour from a person with severe mental health issues and they didn't do anything about it. She didn't test him and basically allowed him to leave. A few hours later [he killed again]." The man said his son told him he had to go have a drug test "so he was expecting it, but nothing came of it". The man's second killing "could and should have been prevented," the father says. "How can someone who has previously killed another person be able to remain free when the warning signs are right there for all to see?" In the weeks leading up to the second killing, the man's mental health was "rapidly declining", a judge earlier said. He was admitted to a mental health facility following an altercation with a relative. About a week later he was released. He was having relationship problems and was using cannabis. Five days after he was released from the mental health facility, he stabbed someone to death. In his letter, he said his son had mental health issues "for most of his life". "I have attended countless appointments and meetings relating to [him] and his treatment, and I have full knowledge of the process, his medication and it's effectiveness, the downsides and how he has responded over the years. "I have met his doctors and psychiatrists and have a good understanding of the mental health system, what services are provided and some of it's failings." He discussed his son's admission to a mental health facility before the second killing when his mental health "deteriorated". He said the staff should not have released his son. The second killing was "predictable if anyone bothered to look at the warning signs and do something about it," he said. "Predictable in the sense that [he] was on a downward spiral. Maybe not predictable with the exact date and time, but the warning signs were there for the health professionals to see. To use their judgement and training and to actually do something about what they saw instead of just letting it go because it gets too hard for them." He said the health system was "not aggressive enough to make decisions". "For more than 5 years I visited [him] every night in one of their institutions, so I know full well what goes on inside the walls. There are more questions than answers. The health system had [him] in their custody and released him. A health professional saw [him] on the day he killed [again], described him as being cagey, did not do the blood test and let him go without doing anything. How? Who is accountable? How can someone who has previously killed another person be able to remain free when the warning signs are right there for all to see?" RNZ put the allegations regarding the drug test to both Health New Zealand and the Ministry of Health. Health New Zealand (HNZ) said an external review of the care the patient received leading up to their alleged offending is in progress. They did not comment on the allegations. In most situations screening for substance use occurred on a voluntary basis and could include individuals subject to detention under the Mental Health Act on Compulsory Treatment Orders, an HNZ spokesperson said. "However, screening is very much part of an individual treatment/care plan where interventions may be put in place in the event of a positive result or refusal to be tested." Director of Mental Health Dr John Crawshaw said in a statement that in circumstances like these an independent review is triggered to investigate the incident and make recommendations for changes to services and for those recommendations to be acted on. A review was still underway. "The claim of reported drug use and delays in drug testing would be most appropriately investigated by the independent review commissioned by Health New Zealand." In relation to drug testing, a Ministry of Health spokesperson said screening for substance use occurred on a voluntary basis and can include individuals subject to detention under the Mental Health Act on Compulsory Treatment Orders. "Screening is very much part of an individual treatment/care plan where interventions may be put in place in the event of a positive result or refusal to be tested. "For further background, it also depends on whether the person is on an inpatient order or a community treatment order. If the testing is part of a condition of leave on an inpatient order it can result in the leave being cancelled. If the person is on a community treatment order, the responsible clinician would then need to assess whether there is enough concern to direct the patient to be treated as an inpatient. It's important to note that this applies to people under ordinary Mental Health Act orders and there is a separate process for special patients." Mental Health Minister Matt Doocey said any serious incident, particularly one where someone was killed was a "cause of very serious concern". "That is why it is important that reviews are triggered and recommendations for changes to services are acted on. My focus is on ensuring agencies involved are putting in place the necessary changes to help prevent these incidents occurring again. "There is an external review underway, and it would be my expectation that this review will cover the care this person received leading up to the incident." Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
Daily Mail
02-07-2025
- Health
- Daily Mail
EXCLUSIVE Sudden death warning over popular party drug as study finds most pills are three times stronger than advertised
Super-strength ecstasy pills containing life-threatening levels of MDMA are back in circulation in the UK as pills return to pre-pandemic strengths, experts warn. Tests carried out on the popular party drug this year showed some pills contained up to 339mg of MDMA, three-times the common dose, an update revealed today. The Loop, a Home Office-licensed drug testing service, found average pill strength has surpassed pre-pandemic levels at 192g—up on the 187mg record last year. Nearly 40 per cent of pills now contain more than 200mg of the stimulant. People have died from taking as little as 150mg of MDMA, though no amount is considered safe. Ahead of festival season, which kicked off with Glastonbury last weekend, the non-profit warned that these changes in the 'MDMA pill market' could pose a serious threat to ecstasy users. In an X, formerly Twitter post, the charity warned people that a single pill does not mean a single dose, highlighting the risks of overdosing—including heart attack, seizures and even death. It marks the first time The Loop has found any pills containing a shocking 340mg of MDMA since before the pandemic. They were identified at Parklife festival in June 2025. MDMA is a stimulant and psychedelic thought to rewire connections in the brain, dampening the part that controls fear. The Loop's testing so far this year indicates changes in the MDMA pill market, which could increase risk to ecstasy users. A single pill is not a single dose. #TakeQuarterSipWater — The Loop (@WeAreTheLoopUK) July 1, 2025 No level of MDMA is considered safe as the drug affects users differently based on their body weight and what other substances are in their system at the time. At Parklife festival last month The Loop tested samples of the pills which had either been seized or disposed of in amnesty bins. They found the tablets were stronger than those that had triggered fits, seizures, heart palpitations and even death. Of all the ecstasy pills tested by The Loop so far this year, just 4 per cent contained no MDMA—a significant decease on 2021 figures when almost half had no traces of the drug. Common risk reduction messages stood up by the charity include 'take a quarter, sip water' and 'go slow, stay low'. Because ecstasy affects the body's ability to regulate temperature, experts are particularly concerned about young people taking the drug at festivals as temperatures continue to climb. According to Talk to Frank, an anti-drug advisory service established by the Department of Health, taking the drug in these conditions increases the risk of dehydration and overheating, which can be fatal. However, the drug-service warns that drinking too much water whilst on MDMA can also be dangerous. This is because the drug can trigger a hormone in the body that prohibits the production of urine, resulting in liver failure. Use of ecstasy has been linked to heart problems with common side-effects including severe agitation, raised body temperatures, fits and irregular heart rhythm. Official figures estimate that around 170 deaths linked to MDMA in the UK every year. Pre-pandemic levels stood at 78. Meanwhile, an estimated 2.4 million people, including 347,000 teenagers, take the drug. It has been classed an illegal substance since 1977 when the government declared it a class A drug, for which the maximum penalty for possession is seven years imprisonment and an unlimited fine. The warning comes following the tragic death of a 17-year-old boy who died after taking ecstasy for the first time during a night out with friends last year. Kristian Jolly, from Norfolk, took at least one pill named 'Andrew Tate' after the self-proclaimed misogynist and social media influencer. Not long after swallowing the pill, Kristian started excessively sweating and became seriously unwell. An ambulance was called the following morning, but Kristian's condition had seriously deteriorated overnight and he was pronounced dead at the scene. The warning comes as the NHS has launched the UK's first ever ketamine teen addiction clinic amid a surge in youngsters hooked on the mind-altering drug.
Globe and Mail
20-06-2025
- Business
- Globe and Mail
Intelligent Bio Solutions (NASDAQ: INBS) to Deploy Fingerprint Drug Testing System Across MWS Sites in Australia
Intelligent Bio Solutions (NASDAQ: INBS) announced that Managed Waste Service (MWS), a leading Australian waste management provider, will implement INBS' Intelligent Fingerprinting Drug Screening System across its New South Wales operations. Covering over 20 remote land clearing and green waste sites, this marks MWS's first shift to in-house, on-site drug testing for pre-employment, random, and for-cause purposes. The fingerprint-based system delivers non-invasive results in under ten minutes, enabling rapid safety decisions without disrupting field operations. INBS continues to expand its reach into safety-critical industries, with its scalable, sweat-based drug testing now in use by over 450 organizations across 24 countries. To view the full article, visit About Intelligent Bio Solutions Inc. Intelligent Bio Solutions Inc. is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners. About BioMedWire BioMedWire ('BMW') is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire Austin, Texas 512.354.7000 Office Editor@ BioMedWire is powered by IBN
